Hepatocellular carcinoma: The role of the North American GI steering committee hepatobiliary task force and the advent of effective drug therapy

Oncologist

Volumn 12, Issue 12, 2007, Pages 1425-1432

  O'Neil, Bert H ^a   Venook, Alan P ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bevacizumab; Chemoembolization; Doxorubicin; Drug therapy; Erlotinib; Hepatocellular carcinoma; Liver neoplasms; Sorafenib

Indexed keywords

5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; BEVACIZUMAB; CAPECITABINE; CISPLATIN; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; FOLIC ACID ANTAGONIST; GEMCITABINE; INTERFERON; IODINATED POPPYSEED OIL; MITOGEN ACTIVATED PROTEIN KINASE; MITOMYCIN C; NOLATREXED; OXALIPLATIN; RAF PROTEIN; SORAFENIB; VASCULOTROPIN;

ADVANCED CANCER; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; EARLY CANCER; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; LIVER CELL CARCINOMA; NORTH AMERICA; PRIORITY JOURNAL; RASH; REVIEW; SURVIVAL RATE; SYSTEMIC THERAPY; TREATMENT INDICATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; HUMANS; LIVER NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIDINES; QUINAZOLINES;

EID: 38049092935     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-12-1425     Document Type: Review

References (33)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-2576.
2. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 1999;19:329-338.
3. The Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients. Hepatology 1998;28:751-755.
4. Leung TW, Tang AM, Zee B et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: A study based on 926 patients. Cancer 2002;94:1760-1769.
5. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation. Hepatology 1999;30:1434-1440.
6. Llovet JM, Real MI, Montana X et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 2002;359:1734-1739.
7. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. N Engl J Med 1995;332:1256-1261.
8. Doffoel M, Vetter D, Bouche O et al. Multicenter randomized phase III trial comparing tamoxifen alone or with transarterial lipiodol chemoembolization (TLC) for unresectable hepatocellular carcinoma (HCC) in cirrhotic patients. Proc Am Soc Clin Oncol 2005;23(suppl 16):309s.
9. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003;37:429-442.
10. Lopez PM, Villanueva A, Llovet JM. Systematic review: Evidence-based management of hepatocellular carcinoma - an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 2006;23:1535-1547.
11. Salem R, Hunter RD. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma: A review. Int J Radiat Oncol Biol Phys 2006;66(2 suppl):S83-S88.
12. Nerenstone S, Friedman M. Medical treatment of hepatocellular carcinoma. Gastroenterol Clin North Am 1987;16:603-612.
13. Porta C, Ruff P, Feld R et al. Results of a phase III, randomized controlled study, the largest ever completed in hepatocellular carcinoma (HCC), comparing the survival of patients with unresectable HCC treated with nolatrexed (NOL) or doxorubicin (DOX). Presented at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium, Orlando, Florida, January 24-26, 2006.
14. Leung TW, Patt YZ, Lau WY et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999;5:1676-1681.
15. Patt YZ, Hoque A, Roh M et al. Durable clinical and pathologic response of hepatocellular carcinoma to systemic and hepatic arterial administration of platinol, recombinant interferon alpha 2B, doxorubicin, and 5-fluorouracil: A communication. Am J Clin Oncol 1999;22:209-213.
16. Yeo W, Mok TS, Zee B et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005;97:1532-1538.
17. Strumberg D, Richly H, Hilger RA et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965-972.
18. Adnane L, Trail PA, Taylor I et al. Sorafenib (BAY 43-9006, Nexavar®), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 2005;407:597-612.
19. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005;23:1028-1043.
20. Schuierer MM, Bataille F, Weiss TS et al. Raf kinase inhibitor protein is downregulated in hepatocellular carcinoma. Oncol Rep 2006;16:451-456.
21. Tannapfel A, Sommerer F, Benicke M et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 2003;52:706-712.
22. Macheiner D, Heller G, Kappel S et al. NORE1B, a candidate tumor suppressor, is epigenetically silenced in human hepatocellular carcinoma. J Hepatol 2006;45:81-89.
23. Huynh H, Soo KC, Chow PK et al. Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. Mol Cancer Ther 2007;6:138-146.
24. Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293-4300.
25. Llovet J, Ricci S, Mazzaferro V et al. Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2007;25(suppl 18):LBA1.
26. Yount S, Cella D, Webster K et al. Assessment of patient-reported clinical outcome in pancreatic and other hepatobiliary cancers: The FACT Hepatobiliary Symptom Index. J Pain Symptom Manage 2002;24:32-44.
27. Hewitt MR, Sun W, Haller DG et al. A phase II trial of combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): Preliminary safety analysis. J Clin Oncol 2006;24(suppl 18):631s.
28. Malka D, Dromain C, Farace F et al. Bevacizumab in patients (pts) with advanced hepatocellular carcinoma (HCC): Preliminary results of a phase II study with circulating endothelial cell (CEC) monitoring. J Clin Oncol 2007;25(suppl 18):215s.
29. Schwartz JD, Schwartz M, Lehrer D et al. Bevacizumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein. J Clin Oncol 2006;24(suppl 18):213s
30. Sun W, Haller DG, Mykulowycz K et al. Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): A phase II study. J Clin Oncol 2007;25(suppl 18):216s.
31. Thomas MB, Chadha R, Iwasaki M et al. The combination of bevacizumab (B) and erlotinib (E) shows significant biological activity in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2007;25(suppl 18):214s.
32. Philip PA, Mahoney MR, Allmer C et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005;23:6657-6663.
33. Miller AA, Murry DJ, Owzar K et al. Pharmacokinetic (PK) and phase I study of sorafenib (S) for solid tumors and hematologic malignancies in patients with hepatic or renal dysfunction (HD or RD): CALGB 60301. J Clin Oncol 2007;25(suppl 18):147s.